Medical analysis services according to the specifications.
Framework Agreements will be concluded with a validity of 24 months, according to the specifications, a period that can be extended by additional act, with the agreement of the parties, for a maximum of 24 months, according to art. 221 para. 1, letter a), Law 98/2016.
We estimate a number of 24 subsequent contracts.
The deadline for requesting clarifications is 15 days before the deadline for submitting offers. The clear and complete answer will be transmitted at least 10 days before the deadline for submitting offers.

LOT-0001
LOT 1 - VARIOUS MEDICAL ANALYSES: BIOCHEMISTRY, IMMUNOLOGY, COAGULATION, VIROLOGY, DRUG DOSAGE, MOLECULAR BIOLOGY, HORMONES.
No. Crt. Name of analysis Estimated quantities Framework agreement (min. / max) Estimated quantities subsequent contract (min / max)
BIOCHEMICAL ANALYSES
1.Folic acid (vitamin B9) 40/100/2/6
2.Vanillylmandelic acid 20/50/1/3
3.Bile acids in serum 20/50/1/3
4.Amino acids in plasma 120/300/6/18
5.Amino acids in urine 8/20/1/3
6.Apolipoprotein A1 20/50/1/3
7.C1 Inhibitor esterase (activity) 18/45/1/3
8.Complement C1 inhibitor esterase 20/50/1/3
9.Urine catecholamines 32/80/2/6
10.Ceruloplasmin 96/240/5/15
11.CK isoenzymes 6/15/1/3
12.Cryoglobulins 10/25/1/3
13.Serum copper 32/80/2/6
14.Urine copper 40/100/2/6
15.Hb electrophoresis 40/100/2/6
16.IgD (immunoglobulin D) 24/60/1/3
17.IGF-binding protein 3 32/80/2/6
18.Interleukin 10 4/10/1/3
19.Serum iodine 4/10/1/3
20.Free plasma metanephrines 28/70/1/3
21.Quantiferon TB test 200/500/10/30
22.Plasma renin 104/260/5/15
23.TNF α 8/20/1/3
24.Acylcarnitine 184/460/10/30
25.Free carnitine in plasma 20/50/1/3
26.Serum organic acids 48/120/3/9
27.Urine organic acids 80/200/4/12
28.NSE (neuron-specific enolase) 28/70/1/3
29.Cystatin C 80/200/4/12
30.Calcitonin 80/200/4/12
31.Homocysteine 20/50/1/3
32.Fibromax 40/100/2/6
33.Carcinoembryonic antigen 12/30/1/3
34.CA 125 10/25/1/3
35.Inhibin B 28/70/1/3
36.Chromogranin A 8/20/1/3
37.Amino acid profile in serum 120/300/6/18
38.Peptide C 120/300/6/18
39.Beta CrossLaps 96/240/5/15
40.Osteocalcin 96/240/5/15
41.Alpha 1 antitrypsin 660/1650/30/90
42.Calprotectin 480/1200/15/45
IMMUNOLOGY ANALYSES
43.Anti beta2 glycoprotein I IgM 16/40/1/3
44.Anti beta2 glycoprotein I IgG 20/50/1/3
45.Anti cyclic citrullinated peptide (CCP) 20/50/1/3
46.Anti TSH receptor antibodies 60/150/3/9
47.Anti glutamic decarboxylase GAD II antibodies 96/240/5/15
48.Anti IA2 antibodies 96/240/5/15
49.Anti insulin-IgG 48/120/3/9
50.Anti ICA (islet cell antibodies) 80/200/3/9
51.Anti Saccharomyces cerevisiae (ASCA) IgG 40/100/2/6
52.Anti Saccharomyces cerevisiae (ASCA) IgA 40/100/2/6
53.Lymphocyte subpopulations (T, B, NK) 44/110/2/6
COAGULATION ANALYSES
54.Anti cardiolipin IgM 28/70/1/3
55.Anti cardiolipin IgG 28/70/1/3
56.Lupus anticoagulant 36/90/2/6
57.Antithrombin III (activity) 28/70/1/3
58.Antithrombin III (antigen) 24/60/1/3
59.Factor IX (activity) 8/20/1/3
60.Factor VIII (activity) 8/20/1/3
61.Factor V (activity) 6/15/1/3
62.Factor VII (activity) 6/15/1/3
63.Von Willebrand Factor (activity) 16/40/1/3
64.Von Willebrand Factor (antigen) 16/40/1/3
65.Free Protein S (antigen) 10/25/1/3
66.Protein S (activity) 20/50/1/3
67.Protein C (activity) 20/50/1/3
VIROLOGY ANALYSES
68.Anti Adenovirus-IgM 16/40/1/3
69.Anti Bartonella henselae-IgM 18/45/1/3
70.Anti Bordetella pertussis Ig A 24/60/1/3
71.Anti Borrelia burgdorferi Ig M 80/200/4/12
72.Anti Borrelia burgdorferi IgG 72/180/4/12
73.Anti Echinococcus granulosus Ig G 12/30/1/3
74.Anti enteroviruses (IgG, IgA, IgM) 8/20/1/3
75.Anti toxocara canis IgG 40/100/2/6
76.Anti rubella virus Ig M 24/60/1/3
77.Anti rubella virus Ig G 24/60/1/3
78.Anti measles virus IgM 24/60/1/3
79.Anti measles virus IgG 20/50/1/3
80.Chlamydia trachomatis IgA 6/15/1/3
81.Anti Coxsackie B virus IgM 36/90/2/6
DRUG DOSAGE
82.Dosage Carbamazepine 16/40/1/3
83.Serum level dosage valproic acid 64/160/3/9
84.Serum level dosage topiramate 6/15/1/3
85.Serum level dosage levetiracetam 20/50/1/3
86.Serum level dosage clonazepam 8/20/1/3
87.Serum level dosage phenobarbital 10/25/1/3
MOLECULAR BIOLOGY ANALYSES
88.CMV DNA 40/100/2/6
89.HBV DNA (quantitative) 24/60/1/3
90.HCV RNA (quantitative) 12/30/1/3
91.Epstein-Barr Virus (EBV) DNA in blood (quantitative) 30/75/2/6
92.Polyoma virus - BK (PCR) quantitative 26/65/1/3
93.HLAB27 10/25/1/3
94.PCR Clostridium difficile 24/60/1/3
HORMONES
95.1,25 dihydroxy vitamin D 72/180/4/12
96.17-hydroxyprogesterone 160/400/7/21
97.Adiponectin 6/15/1/3
98.Aldosterone 100/250/3/9
99.Androstenedione 28/70/1/3
100.Anti-Mullerian hormone 20/50/1/3
101.Leptin 16/40/1/3
102.Free testosterone 36/90/2/6
103.Tyroglobulin 24/60/1/3
104.Total serum triiodothyronine (T3 total) 28/70/1/3
105.Total serum thyroxine (T4 total) 24/60/1/3
106.Free urinary cortisol/24h 20/50/1/3

LOT-0002
LOT 2 - GENETIC ANALYSES.
No. Crt. Name of analysis Estimated quantities Framework agreement (min. / max) Estimated quantities subsequent contract (min / max)
1.Spine muscular atrophy (deletion exon 7 and 8) 2/10/1/2
2.Genetic analysis for muscular dystrophy (deletions/duplications) 2/10/1/2
3.Bone marrow karyotype 20/100/2/4
4.Peripheral blood karyotype 30/170/4/8
5.Factor XIII mutation (G102T) - thrombophilia risk 5/15/1/2
6.Genetic mutations for fragile X syndrome 5/15/1/2
7.Genetic risk profile for thrombophilia (Factor V LEIDEN, FII, PAI-1, MTHFR) 5/15/1/2
8.Gilbert syndrome-genetic testing (UGT1A1 promoter) 2/6/1/2
9.MTHFR gene mutations 5/10/1/2
10.Package for LAM evaluation (FLT3 and NPM1) 5/20/1/2
11.Package for evaluating fusions in ALL (for genes: ETV6-RUN x 1 (TEL-AML): MLL-AF4; BCR-ABL (p190, p210, p230); E2A-PBX1, SIL-TAL1) 15/60/1/2
12.JAK2 mutation 2/6/1/2
13.MELAS syndrome 2/10/1/2
14.MERRF syndrome 2/10/1/2
15.NARP syndrome 2/10/1/2
16.TPMT genotyping 3/12/1/2
17.Cystic fibrosis (screening for 68 CFTR mutations and polymorphism IVS8 5T/7T/9T) 20/80/2/4
18.Genetic testing for MLL-AF4 fusion 2/8/1/2
19.Genetic testing for AML1-ETO fusion 7/20/1/2
20.Genetic testing for PML - RARA fusion 2/8/1/2
21.Package D for hereditary thrombophilias (FVLEIDEN mutation, FII mutation, PAI-1 mutation, MTHFR) 10/40/1/2